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Background: Rare diseases are defined as life-threatening or chronically debilitating diseases with a prevalence of
50 out of 100,000 individuals or less. Orphan medicinal products (OMPs) are intended for the treatment of rare
diseases. The assessment of quality of evidence in small populations is often complex. Many generic tools are unfit.
Therefore, the aim of this study was to develop and validate a new tool to assess the quality of OMPs' clinical
evidence (COMPASS).
Methods: Firstly, a draft version of the COMPASS tool, developed by the authors and consisting of three parts, was
amended based on suggestions obtained in four rounds of expert consultation. Secondly, the tool was put through
three rounds of validation. The data source was information provided on the Orphanet website and in European
Public Assessment Report (EPAR) document of the European Medicines Agency.
Results: The first pilot round revealed a high (92.2%) inter-rater agreement for part one of the tool. After further
improvements, the final inter-rater agreement was 86.4% for part two (on methodological quality) and three
(on quality of reporting) of the tool. The COMPASS tool does not attempt to score or rank the quality of clinical
evidence, but rather to give an outline of various, key elements with respect to quality of clinical evidence of
OMP studies.
Conclusions: The COMPASS tool can be applied to assess the quality of evidence of an OMP based on information
in the registration dossier, for example by local reimbursement agencies, pharmacists or clinicians. In that way, the
tool can contribute to making reimbursement and/or treatment decisions increasingly more founded on the
principles of evidence-based decision making.
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Rare diseases are defined as life-threatening or chronic-
ally debilitating diseases with a prevalence of 50 out of
100,000 individuals or less [1]. It is estimated that there
are currently between 5,000 and 7,000 rare diseases [2].
Orphan medicinal products (OMPs) are intended for the
treatment of rare diseases [1]. Studies to evaluate the
effect of an OMP in patients with rare diseases are often
hampered by the difficulty of enrolling a sufficient num-
ber of patients [3,4]. For example, N-acetylglutamate* Correspondence: eline.picavet@pharm.kuleuven.be
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reproduction in any medium, provided the orsynthase (NAGS) deficiency is a very rare disorder that
can cause neonatal life-threatening hyperammonemia.
To date, only few patients with NAGS deficiency have
been identified. In Europe, treatment with carglumic
acid for NAGS deficiency has been authorized based on
efficacy data from four case reports and 12 patients in a
retrospective data collection study [5,6]. For some
OMPs, it is clear that the quantity of clinical evidence
cannot be obtained. Even so, achieving the highest qual-
ity of evidence should still be aimed for [7].
But how do we define quality of clinical evidence?
According to GRADE (Grading of Recommendations
Assessment, Development and Evaluation), quality of
evidence reflects the extent of our confidence that theLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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domized controlled studies are regarded as the gold
standard in achieving high quality of evidence whereas
case controls or case studies are considered of lesser, but
not lacking, value [7,9,10]. Nevertheless, high quality evi-
dence is needed to guide clinical decision-making [11].
The assessment of quality of evidence in small popula-
tions at the time of registration and/or reimbursement is
often complex. However, the rising number of autho-
rized OMPs and their increased use in clinical practice
emphasizes the need for an objective assessment. Quality
assessment involves evaluation of a study’s validity, i.e.
the degree to which its design, conduct and analysis have
minimised biases or errors [12]. In general, there are
three ways to assess the quality of studies: individual
markers, checklists and scales [13-15]. Many generic
tools, from simple checklists to extensive questionnaires,
are currently used to assess studies [12,16]. However, the
majority of these instruments are unfit to assess clinical
studies of OMPs, as they do not take into consideration
the difficulties (ie small sample size, use of surrogate
endpoints, etc.…) that are inextricably bound up with
these studies. According to Khan, new tools can be de-
veloped, keeping in mind that all components of the tool
should be selected with due consideration for its pur-
pose. These components should capture both generic
methodological issues and issues specific to the subject
under review [12].
Therefore, the aim of this study was to develop and val-
idate a new tool, COMPASS (Clinical evidence of Orphan
Medicinal Products – an ASSessment tool), to assess the
quality of OMPs clinical evidence that is presented for
OMPs at the time of marketing authorization in the EU.
Methods
Design of the tool
The design of the tool was conceptualised after consult-
ing the Centre for Evidence-Based Medicine (CEBAM),
Leuven, Belgium. A draft version of the tool was drawn
up based on elements derived from existing checklists
supplemented with items specifically related to rare
diseases and OMPs [13-15].
Validity of the COMPASS tool
The draft version of the tool was proofread by two lay-
men to increase readability. Subsequently, four expert
consultations were organised with six experts (in a two-
two-one-one fashion) with a view to increasing content
validity (Table 1). All consultations were audio-taped
and transcribed verbatim. The transcripts were analyzed
in three steps. The first step was aimed at familiarizing
with the data by reading and re-reading the transcripts.
Secondly, a framework of key issues was identified. Finally,
all issues were grouped according to the framework andinterpreted. The draft version of the tool was adapted in
accordance with all relevant issues, as deemed upon
consensus by the researchers, raised at all consultations.
Data source
The data source of the tool consisted only of information
provided on the Orphanet website and in European Public
Assessment Report (EPAR) and/or the Scientific Discussion
(SD) document prepared by the Committee for Human
Medicinal Products (CHMP) of the European Medicines
Agency (EMA). These documents provide information
about chemical, pharmaceutical, biological, toxico-phar-
macological and clinical aspects of a drug [5]. For practical
and privacy reasons, we did not have access to the original
documents submitted to EMA. However, we anticipated
that the publicly EPARs sufficiently reflect these original
documents. The assessment of the methodological quality
was restricted to studies that were described as ‘pivotal’ or
‘main’ clinical studies. The analyses were performed per
study, as opposed to per orphan medicinal product, due
to possible methodological differences between the stud-
ies. No additional data from publications of those studies
was used due to possible unsystematic reporting and
publication bias.
Consistency of the COMPASS tool
A first pilot round was undertaken, in which five
randomly selected OMPs (i.e. one from each “type”: beta-
ine anhydrous (one indication, only literature reports),
histamine dihydrochloride (one indication, open label
study), idursulfase (one indication, RCT), pirfenidone (one
Table 2 Expert consultation - number of issues discussed
Number of issues discussed
Expert consultation #1 44
Expert consultation #2 53
Expert consultation #3 48
Expert consultation #4 42
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RCTs)) were analysed by two raters (E.P. and S.S.). The
two raters completed all three parts of the COMPASS
tool. A second pilot round was undertaken, in which four
alphabetically successive OMPs (ziconotide, agalsidase
alfa, sildenafil citrate and lenalidomide) were analysed by
two raters (E.P. and D.C.). One rater completed all three
parts of the tool, whereas the other completed the second
and third part. The final version (Additional file 1) of the
COMPASS tool was drawn up in accordance with the
issues raised during the two pilot rounds.
The COMPASS tool consists of three parts; the first
part collects general descriptive information about the
OMP and its marketing authorization. The second part
focuses on the assessment of the methodological quality
(i.e. specifically related to study design, patient and study
population, control arm, blinding, randomization and
allocation, outcomes, adherence and statistical analysis)
of the study. The last part assesses the quality of
reporting. The Orphanet website was consulted to pro-
vide information on the prevalence of the rare disease in
which the indication is authorized and its therapeutic
need [2]. The registration of the pivotal studies on
EudraCT and/or clinicaltrials.gov was evaluated on their
respective websites [17,18].
In a third and final round, two raters (E.P. and S.S.)
completed the tool for a sample of OMPs (n = 29). One
rater (E.P.) completed all three parts of the tool, whereas
the other (S.S.) completed the second and third part.
Additionally, expertise in the medical field was believed
necessary to answer the question “Is the duration of the
study relevant to the natural history of the disease?”.
Therefore, a third rater (D.C.) (ie a trained physician)
also answered this question for all 29 OMPs. Upon dis-
agreement between the raters, the assessment of D.C.
was considered decisive.
In all three rounds, raters completed the tool independ-
ently and once-only. Additionally, raters were blinded with
respect to results of others. The same information was
available to all raters. After data collection, E.P. was
responsible for comparison of the results.
Analysis
All analyses (including the calculation of inter-rater
agreement, by percent agreement calculation) were per-
formed using MS Office Excel 2010.
Results
Validity of the COMPASS tool
During the expert consultations, a number of issues
were discussed related to both the design (for example,
on the sub-classification of the tool into three parts) and
to the content of the tool (for example, on how to define
a valid method of randomization). The total number ofissues discussed per consultation is shown in Table 2.
All relevant suggestions were implemented.
Consistency of the COMPASS tool
The inter-rater agreement rates of the three rounds are
shown in Table 3. In the first round, the overall inter-
rater agreement was 87.1%. Also, there were small
anomalies (ie when one rater answered ‘No’ and the
other answered ‘Not reported’) for 3.7% of the answers.
There was a slight increase in inter-rater agreement in
the second round. Additionally, there was less (1.6% of
the answers) confusion between ‘No’ and ‘Not reported’.
However, this rate increased to 6.2% in the third round.
In all rounds, disagreements between the raters were
able to be resolved upon reviewing the data.
All three raters independently evaluated the relevance
of the study duration with respect to the natural history
of the disease. There was agreement between three
raters for 65.4% of the studies. In case of disagreement,
the rater with a medical background was more inclined
to assess the study duration as appropriate (77.8%) than
raters without a medical background (E.P. 27.8% and S.S.
22.2%). Additionally, the raters without a medical back-
ground experienced more difficulties in evaluating study
duration, as shown by their choice of “Don’t know”
respectively nine and two times.
Discussion
The goal of this research was to develop and validate a
new tool COMPASS to assess the quality of OMPs clinical
evidence presented at the time of marketing authorization
in the EU. The COMPASS tool (Additional file 1) does
not attempt to score or rank the quality of clinical
evidence, but rather to give an outline of various, key
elements with respect to quality of clinical evidence, as
seen by experts. Ultimately, it is up to the evaluator to de-
fine minimum conditions of quality for an individual
OMP or a set of similar OMPs. Ideally, these conditions
should be defined without taking into account unmet
need and disease severity, as these are not determining
factors for quality of clinical evidence.
This COMPASS tool can be applied to assess the qual-
ity of evidence of an OMP based on the information in
the registrations dossiers, for example by local reim-
bursement agencies for the review of clinical evidence or
Table 3 Inter-rater agreement
Inter-rater agreement (%)
Overall Part 1 Part 2 Part 3
1st pilot round (n = 5) 87.1 92.2 76.9
2nd pilot round (n = 4) NA NA 77.5
3rd round (n = 29) NA NA 86.4
n, number of orphan medicinal products under review; NA, not applicable.
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treatment. Registration and reimbursement bodies cur-
rently acknowledge the data limitations for OMPs by
providing them special considerations [19]. However,
over time they are likely to become more sensitive to
data requirements [20]. For example, non-binding rec-
ommendations for the approval of cancer drugs and bio-
logics were issued by the Food and Drug Administration
(FDA) several years ago [21]. Nowadays, deviations from
the guidelines, stated in a similar European document,
should be thoroughly justified [22].
To improve the reliability of results, data extraction
should be performed independently by at least two raters.
The reliability of results has shown to be independent of
blinding, for that reason data extraction should not neces-
sarily be blinded [12]. An exception on the number of
raters can be made for the first part of the tool, as it col-
lects more general and descriptive information about the
OMP. Yet, minor differences between the raters can occur
depending on the information source. To reduce variabil-
ity, the source of information was pre-specified for some
queries (ie specified the source of prevalence data to EPAR
and Orphanet). There are more subjective questions in
part two of the tool, emphasizing the need for indepen-
dent raters.
Study quality is dependent, not only on methodo-
logical quality, but also on the quality of reporting [14].
Indeed, shortcomings in the reporting can complicate
the interpretation of the methodological quality. Cor-
rect and complete information should provide the
reader with the ability to make informed judgements
about the validity of a study [23]. In practice, it was
(nearly) impossible to assess the methodological quality
of those (few) studies that were only very briefly
discussed in the EPAR. Additionally, the interpretation
was also complicated for those EPARs that consisted
only of literature studies. To address the issue of poor
reporting, part three of the tool focuses on quality of
reporting. Additionally, for some questions, an add-
itional check box was provided with ‘Not reported’.
Whilst in some cases the difference between answering
‘No’ or ‘Not reported’ may be vague, the subtle dif-
ference influences the evaluation of the quality of
reporting.The COMPASS tool has several strengths and
weaknesses. The tool was developed after iterative
rounds of expert consultation and underwent several
pilot rounds to increase its validity. The tool assesses
the level of clinical evidence that is presented in the
pivotal studies at the time of marketing authorization.
As such, it does not take into consideration the evi-
dence in any of the supporting studies or evidence
generated as part of post-marketing commitments.
Adding data from publications would allow for quality
control of the EPAR data, but was considered outside
the scope of this study. Also, the tool is dependent
on the quality of reporting in the EPAR and/or SD
documents. Finally, a general medical knowledge of
the rater is advisable to complete the tool. Additional
check boxes (‘Don’t know’ and ‘Not reported’) were
provided, to account for possible problems related to
these last issues.Conclusions
In conclusion, we developed and validated a new tool for
the assessment of clinical evidence of OMPs. The COM-
PASS tool can for example be used by local reimburse-
ment agencies for the review of clinical evidence from
OMP registration dossiers or by clinicians and pharma-
cists upon considering a (new) treatment. Furthermore,
we hope that the COMPASS tool can initiate and add to
the open debate on study standards for orphan medi-
cinal products. In that way, the COMPASS tool can con-
tribute to making reimbursement decisions increasingly
more founded on the principles of evidence-based deci-
sion making.Additional file
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